New analyses of real-world data (RWD) presented at the European Academy of Dermatology and Venereology (EADV) Congress reinforce the effectiveness of apremilast in treating psoriatic disease, including psoriasis and psoriatic arthritis. The data, derived from the extensive Psoriasis Registry of the German Dermatological Therapy Guidelines (PSORT), provide valuable insights into how the drug performs outside of controlled clinical trials, offering a more comprehensive understanding of its benefits and safety profile.
The PSORT registry encompasses data from over 18,000 patients with psoriasis, making it one of the largest and most robust RWD sources available for this condition. Researchers leveraged this wealth of information to assess apremilast’s performance in patients who had previously failed, or were intolerant to, other systemic treatments. The findings consistently demonstrated significant improvements in disease severity, as measured by the Psoriasis Area and Severity Index (PASI), and in patient-reported outcomes.
Key Findings from PSORT Analyses
One key analysis focused on patients initiating apremilast after failing TNF inhibitors, a commonly used class of biologic drugs. Results showed that a substantial proportion of these patients achieved clinically meaningful responses with apremilast, defined as a 75% reduction in PASI score (PASI 75). This suggests apremilast can be a valuable treatment option for patients who do not respond adequately to TNF inhibitors.
Further analyses explored the long-term effectiveness of apremilast. Data indicated that patients maintained their improvements over extended periods, with many continuing to experience significant benefits for up to two years. This sustained response is particularly encouraging, as maintaining treatment efficacy is a major challenge in managing chronic conditions like psoriatic disease.
The RWD also provided reassurance regarding the safety of apremilast. While some adverse events were reported, the overall safety profile was consistent with that observed in clinical trials. Notably, the incidence of serious adverse events was relatively low, suggesting that apremilast is generally well-tolerated in real-world clinical practice.
These findings are particularly important as healthcare systems increasingly rely on RWD to inform treatment decisions and optimize patient care. RWD can complement clinical trial data by providing information on a broader and more diverse patient population, reflecting the complexities of real-world clinical settings. The PSORT registry, in this instance, offers a valuable resource for understanding the long-term effectiveness and safety of apremilast in patients with psoriatic disease.
Researchers emphasize that these analyses support the use of apremilast as an effective and safe treatment option for patients with psoriasis and psoriatic arthritis, especially those who have not responded to other therapies. The data contribute to a growing body of evidence demonstrating the value of apremilast in improving the lives of individuals affected by these chronic inflammatory conditions. Future research will likely continue to leverage RWD to further refine our understanding of apremilast’s optimal use and identify potential predictors of treatment response.
Image Source: Google | Image Credit: Respective Owner
